University of Nevada, Reno School of Medicine

Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023

Retrieved on: 
Monday, June 26, 2023
University of Southern California, DME, Stanford University, Partner (business rank), Teaching hospital, Alcon, Lotte New York Palace Hotel, SAB, University, Neuroscience, OCS, Genentech, Stanford University School of Medicine, Retina, POC, Keck School of Medicine of USC, Neuro-ophthalmology, Master of Science, Clinical research, Webcast, CME, Drug development, University of Paris, Q&A, AON, University of Nevada, Reno School of Medicine, Diabetic retinopathy, Reno 1868 FC, Neuro, Medical director, Novartis, Fellow, USC Eye Institute, Tourism, Pharmaceutical industry, Management, Development, Ophthalmology, MD, Pecten oculi, Medicine

ZUG, Switzerland and BOSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that it will host its first R&D Day featuring multiple experts to showcase its clinical programs targeting retina diseases on Tuesday, July 11, 2023, from 10:00 AM – 12:00 PM EDT.

Key Points: 
  • ZUG, Switzerland and BOSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that it will host its first R&D Day featuring multiple experts to showcase its clinical programs targeting retina diseases on Tuesday, July 11, 2023, from 10:00 AM – 12:00 PM EDT.
  • Those interested can participate in the event either in-person at the Lotte New York Palace Hotel, or virtually via webcast.
  • To register for the event, please click here .
  • The additional expert panelists participating in the Q&A session include:
    Pravin Dugel, MD: Oculis Board of Directors member, retina specialist, and President of Iveric Bio.

Reno Gynecology and Comprehensive Women's Health Clinic, FEM Women's Wellness, Welcomes Dr. Yizhou Du Ernst to the Practice

Retrieved on: 
Monday, May 8, 2023
Insurance, Medical school, Communication, University, North American Menopause Society, American College of Obstetricians and Gynecologists, Teaching, Birth, Woman, Attention, University of Nevada, Reno School of Medicine, Patient, Physician, Mental, School, Health, Menopause, American College, Gynaecology, Mental health, Environment, Education, Female, Wellness, Birth control, Barnabas

RENO, Nev., May 8, 2023 /PRNewswire-PRWeb/ -- From contraception and preventive gynecological care to mental health therapy and cosmetic services, FEM Women's Wellness is the premier source for personalized women's healthcare in the Reno and Lake Tahoe, NV, area. The team is thrilled to share that Dr. Yizhou Du Ernst has joined the practice. As an accomplished gynecologist, Dr. Ernst enjoys the privilege of taking care of women throughout their lives; from their first period to their transition into menopause and beyond. Although she specializes in complete gynecologic care for all ages, she has a particular interest in menopausal medicine. Her treatment philosophy stems from having attended an osteopathic medical school and involves the integration of the mind and body. Additionally, Dr. Ernst is a skilled laparoscopic and robotic surgeon and specializes in all forms of minimally invasive surgical techniques. She is an active member of the North American Menopause Society as well as the American College of Obstetricians and Gynecologists. Dr. Ernst is involved in teaching and was the Chief of Education in her final year of residency at St. Barnabas. In addition to being a community faculty member for the University of Nevada Reno's School of Medicine, Dr. Ernst is also active in volunteering with the UNR Student Outreach Clinic, where she supervises young training physicians who provide free medical care to the Reno community.

Key Points: 
  • The team is thrilled to share that Dr. Yizhou Du Ernst has joined the practice.
  • Additionally, Dr. Ernst is a skilled laparoscopic and robotic surgeon and specializes in all forms of minimally invasive surgical techniques.
  • Providing compassionate care and individualized attention with clear communication when treating patients is my goal," says Dr. Yizhou Du Ernst.
  • For more information or to schedule an appointment at FEM Women's Wellness, please visit http://www.femwomenswellness.com or call (775) 993-9292.

Clearside Biomedical Enhances Scientific Advisory Board with the Appointment of Two Distinguished Retinal Physicians

Retrieved on: 
Wednesday, April 5, 2023
Society, Pharming, Emerging, CLS, Associate, Patient, Premature, SCS, SAB, University, Heredity, Duke University School of Medicine, United States Air Force Scientific Advisory Board, Research, Retinal, Retinopathy, Artificiality, M.A, Diabetic retinopathy, Treasurer, ASRS, Duke University, Eye, Bascom Palmer Eye Institute, Clinical research, Argus, University of Nevada, Reno School of Medicine, American Academy, Retina, Reno 1868 FC, Clinical trial, Physician, Fellow, Duke, Nursing, Medical device, Dentistry, Ophthalmology, Woman, Medicine

Clearside’s SAB is comprised of industry leading retinal physicians who provide medical and scientific expertise and input on the Company’s research and development programs.

Key Points: 
  • Clearside’s SAB is comprised of industry leading retinal physicians who provide medical and scientific expertise and input on the Company’s research and development programs.
  • Khanani and Vajzovic will greatly complement our highly experienced SAB, led by Dr. Thomas Ciulla as Chair.
  • She is passionate about translational research and collaborates closely with Duke Biomedical engineers to develop imaging devices to improve ophthalmic care.
  • She is an elected member of the Retina Society, Macula Society and Club Jules Gonin Society.

Oculis completes patient recruitment for stage 1 of Phase 3 DIAMOND study evaluating the efficacy and safety of OCS-01 in diabetic macular edema (DME)

Retrieved on: 
Thursday, January 5, 2023
Acta Ophthalmologica, Clinical research, Dexamethasone, CST, Diabetic retinopathy, Angiogenesis, Patient, Macular edema, Keck School of Medicine of USC, Physician, Safety, University, University of Nevada, Reno School of Medicine, University of Nevada, Reno, Conference, University of Southern California, Visual acuity, Quality of life, SD, DME, Pharmaceutical industry, Ophthalmology, Massilia oculi

At the end of 2021, Oculis launched its 2 stage Phase 3 DIAMOND study, a double-masked, randomized, vehicle-controlled, multi-center, multi-country study of OCS-01 in patients with DME.

Key Points: 
  • At the end of 2021, Oculis launched its 2 stage Phase 3 DIAMOND study, a double-masked, randomized, vehicle-controlled, multi-center, multi-country study of OCS-01 in patients with DME.
  • Several vision and anatomical secondary endpoints are also planned, including the mean change in macular thickness (CST, central subfield thickness) measured by SD-OCT (spectral domain optical coherence tomography) from baseline.
  • Riad Sherif, M.D., CEO of Oculis, said: "I am delighted Oculis has completed patient enrollment for stage 1 of our DIAMOND study.
  • At present, OCS-01, developed using the proprietary Optireach® technology, seems to be one of the most promising drug candidates in Phase 3.

Successful Citizen Science Weather Tracking Effort Goes National, Receives Three Additional Years of Funding From NASA

Retrieved on: 
Tuesday, November 29, 2022
Nevada System of Higher Education, Reno 1868 FC, Snow, Environment, Science, Carnegie Classification of Institutions of Higher Education, Hydrology, University of Nevada, Reno, Engineering, University, Geology, Desert Research Institute, Doctor of Philosophy, Student, Knowledge, Community, Cardamom Mountains rain forests, Policy, Wasatch Range, Database, DRI, Temperature, Classification, Education, Faculty, University of Nevada, Reno School of Medicine, Rain, Freezing, Research, Human, Citizen science, Water resources, Safety, Satellite navigation device, Management, Rocky Mountains, Western Montana

The project has been so successful at collecting data that demonstrates regional variation in the rain-snow threshold that NASAs Citizen Science for Earth Systems Program is funding an additional three years.

Key Points: 
  • The project has been so successful at collecting data that demonstrates regional variation in the rain-snow threshold that NASAs Citizen Science for Earth Systems Program is funding an additional three years.
  • The project began in 2019 as Tahoe Rain or Snow and expanded last year to include mountain regions across the country.
  • Direct observations, made by people, are the most accurate way to discover how precipitation phase varies in time and space.
  • In the Rockies, the snow-rain threshold is closer to 40 degrees, while its around 33 degrees in the Northeast.

Approval of New Pediatric Physician Residency Program Helps Improve Care for Children and Families in Nevada

Retrieved on: 
Thursday, September 22, 2022
Pediatrics, Elective surgery, University of Nevada, Reno, Internal medicine, Patient, Emergency medicine, Physician, GME, Renown Health, Research, VP, Workforce, Accreditation, Graduate medical education, Growth, University of Nevada, Reno School of Medicine, MBA, Student, Accreditation Council, National Medical Commission, Technology, Doctor of Philosophy, FAAP, Innovation, Segal Design Institute, Education, Hope, Mentorship, Â, Interim, GLOBE, Health, Faculty, Psychiatry, Program, ICU, ACGME, Renown, Nell, College of Arts and Sciences, Retirement, University, Medicine, Management, MD

The new residency will help shape future pediatric practices and fill a state and nation-wide physician specialist shortage.

Key Points: 
  • The new residency will help shape future pediatric practices and fill a state and nation-wide physician specialist shortage.
  • The Nell J. Redfield Foundation donated $1.5M towards this initiative and expressed the hope to see a pediatric residency program established for the community.
  • Prior to 2016, about 30%of all pediatric patients had to leave northern Nevada to receive the specialty care they needed.
  • Now, thanks to donor support, Renown estimates that 97% of all pediatric patients and their families can receive both general and specialty pediatric care locally.

Adverum Biotechnologies Completes IND Amendment and Prepares to Initiate the Phase 2 LUNA Trial of ADVM-022 in Wet AMD

Retrieved on: 
Wednesday, July 6, 2022
VEGF, Review, FDA, OPTIC, Injection, Patient, European Medicines Agency, University of Nevada, Reno School of Medicine, Macular degeneration, Research, NAMD, University of Nevada, Reno, Severe cognitive impairment, M.A, GLOBE, AAV, Difluprednate, Retina, Union, U.S. Securities and Exchange Commission, Inflammation, Compliance, Prevalence, World, Â, Food, State, Neovascularization, IND, Private Securities Litigation Reform Act, Heel, Technology, University, Standard of care, Nasdaq, SEC, Incidence, AMD, NASDAQ, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LUNA, IVT, Pharmaceutical industry, Adverum Biotechnologies

REDWOOD CITY, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that it has completed its Investigational New Drug (IND) amendment with the U.S. Food and Drug Administration (FDA) and is preparing to initiate the Phase 2 LUNA trial of ADVM-022, a single intravitreal (IVT) injection for wet age-related macular degeneration (wet AMD). The World Health Organization’s Review Council and the U.S. Adopted Names Council has adopted the name ixoberogene soroparvovec (Ixo-vec) for ADVM-022 as the international nonproprietary name.

Key Points: 
  • We amended our IND and are on track to dose the first patient in the Phase 2 LUNA trial for the treatment of wet AMD in the coming months.
  • We are excited to initiate our Phase 2 LUNA trial this quarter.
  • The LUNA trial is a multicenter, double-masked, randomized, parallel-group Phase 2 trial evaluating two doses of Ixo-vec, including the 2x10^11 vg/eye dose and a new, lower 6x10^10 vg/eye dose, in wet AMD.
  • Wet AMD, also known as neovascular AMD or nAMD, is an advanced form of AMD, affecting approximately 10% of patients living with AMD.

Bellevue Psychiatric Urgent Care Providing Expert Psych Services at Affordable Rates

Retrieved on: 
Wednesday, May 4, 2022
American, University, American Psychiatric Association, American Board of Psychiatry and Neurology, Patient, Neurology, University of Nevada, Reno School of Medicine, Psychiatry, Mental health, American Board of Commissioners for Foreign Missions, Reno 1868 FC, Medicine, Hospital

JACKSONVILLE, Fla., May 4, 2022 /PRNewswire/ -- Bellevue Psychiatric Urgent Care, a leader in psychiatric patient care, is announcing it is the first and only psychiatric urgent care in North Florida to serve those in desperate need and have limited access to mental health services."We are here to serve the growing population of low-income communities, underserved areas, and those in dire need of psychiatric care with our walk-in, same day and telehealth visits," says the founder of Bellevue Psychiatric Urgent Care, Dr. Bih Tambi."The United States suffers from a dramatic shortage of psychiatrists, leaving individuals and families without mental health services they desperately need.  Our team aids in this shortage by skipping roadblocks to get immediate, convenient, and affordable mental health treatment."We treat different conditions adults and children over the age of seven including

Key Points: 
  • Bellevue Psychiatric Urgent Care was founded in 2015 by Dr. Bih Tambi, a distinguished fellow of the American Psychiatric Association.
  • She is certified by the American Board of Psychiatry and Neurology and is a licensed psychiatrist in Florida, Georgia, California, Virginia, and Nevada.
  • Bellevue Psychiatric Urgent Care aims to cut wait times by helping patients skip roadblocks and get immediate, convenient, and affordable mental health treatment.
  • The clinic also provides services on a walk-in basis, including extended Saturday opening times.

Nanoscope Therapeutics Announces 3 New Appointments to its Scientific and Clinical Advisory Board

Retrieved on: 
Monday, April 4, 2022
Therapy, Doctor of Science, Atomic de Broglie microscope, MA, Clinical research, Macular degeneration, Duke University Hospital, MCO, Retina, RP, Research, Coronavirus Scientific Advisory Board (Turkey), Associate, Consultant, Houston Methodist Hospital, Reno 1868 FC, University of Nevada, Reno School of Medicine, Physician, Fellow, Retinitis pigmentosa, FDA, Geographic atrophy, University, Patient, Pharmaceutical industry, Stargardt disease, Ophthalmology, MD

DALLAS, April 4, 2022 /PRNewswire/ -- Nanoscope Therapeutics , Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced expansion of its Clinical and Scientific Advisory Board to include three newly appointed members.

Key Points: 
  • DALLAS, April 4, 2022 /PRNewswire/ -- Nanoscope Therapeutics , Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced expansion of its Clinical and Scientific Advisory Board to include three newly appointed members.
  • Arshad Khanani, MD, MA, Managing Partner, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates, Reno; and Clinical Associate Professor at the University of Nevada, Reno School of Medicine.
  • The company also expects to begin Phase 2 clinical trials of a follow-on asset targeting Stargardt macular degeneration in H1-2022.
  • Nanoscope Therapeutics is developing optogenetic therapies to restore sight in millions of patients blinded by retinal degenerative diseases, for which no cure exists.

Graybug Vision to Host Virtual R&D Day on March 30, 2022

Retrieved on: 
Monday, March 21, 2022
Private Securities Litigation Reform Act, Retina, University, Form 10-K, MA, Investor, Pediatric ophthalmology, Forward-looking statement, ID, Clinical research, Annual report, University of California, Irvine School of Medicine, University of California, SEC, Doctor of Philosophy, Sunitinib, Webcast, Medical director, U.S. Securities and Exchange Commission, Johns Hopkins School of Medicine, Technology, Karger Publishers, VEGF, Reno 1868 FC, Institute, COVID-19, MBA, University of Nevada, Reno School of Medicine, GLOBE, Fellow, Disease management, Division, CHOC, Security (finance), Pharmaceutical industry, Medicine, Ophthalmology, MD

BALTIMORE, March 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that it will host a virtual Investor R&D Day from 11 a.m. - 12:45 p.m.

Key Points: 
  • BALTIMORE, March 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that it will host a virtual Investor R&D Day from 11 a.m. - 12:45 p.m.
  • Additionally, Graybug will provide a strategic outlook.
  • Attendees may also participate by dialing (844) 955-2748 (domestic) or (929) 517-0407 (international) and entering the conference ID# 9785187.
  • Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases.